


What is claimed is

1. A compound of the formula I, or a salt, solvate, or a physiologically functional derivative thereof

5




I

in which

10

M is a radical of the formula



Y is a radical of the formula

15




R1, R2 and R3 are independently hydrogen, -NH₂, halogen, -OC₁₋₆alkyl, -CF₃, -N(C=O)CH₃, -(C=O)OH, -CF₃, -(C=O)NH₂, -SO₂CH₃, -SO₂OH, or -C₁₋₆alkyl;

W is $-(CH_2)_n-$, in which n is 0 to 2; and


R4 is $\cdot NH_2$, or $\cdot OH$; and

5 R5 and R6 are independently hydrogen or halogen.

2. A compound of Formula I of claim 1 in which M is a radical of the formula



Y is a radical of the formula



10

in which R2 is hydrogen, $\cdot NH_2$, halogen, $\cdot OC_1\text{-}6$ alkyl, $\cdot CF_3$, $\cdot N(C=O)CH_3$, $\cdot (C=O)OH$, $\cdot CF_3$, $\cdot (C=O)NH_2$, $\cdot SO_2CH_3$, $\cdot SO_2OH$, or $\cdot C_1\text{-}6$ alkyl.

15 3. A method of inhibiting hYAK3 and/or CK2 in a mammal; comprising, administering to the mammal a therapeutically effective amount of a compound of

formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof.

4. A pharmaceutical composition including a therapeutically effective amount of
5 a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

5. A method of treating or preventing diseases of the erythroid and
10 hematopoietic systems selected from the group consisting of: neutropenia; cytopenia; anemias, including anemias due to renal insufficiency or to a chronic disease, such as autoimmunity, HIV or cancer, and drug-induced anemias; and myelosuppression; comprising administering to a mammal a therapeutically effective amount of a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

6. A method of treating or preventing cancer or viral infections; comprising administering to a mammal a therapeutically effective amount of a compound of formula I of claim 1, or a salt, solvate, or a physiologically functional derivative thereof and one or more of pharmaceutically acceptable carriers, diluents and excipients.

7. A compound of formula I of any of claim 1, 3, 4, 5, or 6 selected from the
25 group consisting of
4-anilino-5-carboxyl-2-(4-methoxyphenyl)thiazole;
4-anilino-5-methoxycarbonyl-2-(4-methoxyphenyl) thiazole;
5-aminocarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;
5-methoxycarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino) thiazole;
30 5-carboxyl-2-(4-methoxyphenyl)-4-(2-trifluoromethyl)anilinothiazole;
5-aminocarbonyl-2-(3-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;
5-carboxyl-4-(3-fluoroanilino)-2-(4-methoxyphenyl)thiazole;
5-carboxyl-2-(4-methoxyphenyl)-4-(2-trifluoromethylanilino)thiazole;.

4-anilino-5-carboxyl-2-(3-methoxyphenyl)thiazole;
5-carboxyl-4-(2-fluoroanilino)-2-(3-methoxyphenyl)thiazole;
4-benzylamino-5-methoxycarboxyl 2-(4-methoxyphenyl)thiazole
4-(2-chlorophenylamino)-2-(2,3-dihydro-benzofuran-5-yl)-thiazole-5-carboxylic acid
5 ethyl ester;
4-(2-chlorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic acid;
4-(2-chlorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic acid
amide;
4-(2-chloro-5-fluorophenylamino)-2-(2,3-dihydrobenzofuran-5-yl) thiazole-5-carboxylic
10 acid amide;
4-(2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;
4-(5-acetylamino-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic
acid;
4-(5-carbamoyl-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;
15 4-(2-chloro-5-sulfophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;
4-(5-amino-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;
4-(2-chloro-4-methanesulfonylphenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic
acid;
4-(4-carboxy-2-chlorophenylamino)-2-(4-methoxyphenyl) thiazole-5-carboxylic acid;
20 4-(2-chlorophenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;
4-(3,5-dichloropyridin-4-ylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;
2-pyridin-3-yl-4-(pyridin-3-ylamino)-thiazole-5-carboxylic acid;
4-(2-chlorophenylamino)-2-(pyridin-4-yl)-thiazole-5-carboxylic acid;
4-[2-(3-chlorophenyl) ethylamino]-2-(pyridin-4-yl) thiazole-5-carboxylic acid;
25 4-[2-(3-chlorophenyl) ethylamino]-2-(pyridin-4-yl)-thiazole-5-carboxylic acid amide;
4-(2-chloro-5-fluorophenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid;
4-(2-chloro-5-fluoro-phenylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid amide;
2-(pyridin-3-yl)-4-(2-trifluoromethyl-phenylamino) thiazole-5-carboxylic acid amide;
4-(4-chlorobenzylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid; and
30 4-(4-chlorobenzylamino)-2-(pyridin-3-yl) thiazole-5-carboxylic acid.